What is SkinJect?
SkinJect operates as a specialized development-stage enterprise dedicated to transforming the standard of care for non-melanoma skin cancers. The company's core innovation centers on a novel dissolvable microneedle patch designed to treat basal and squamous cell carcinomas. By providing a minimally invasive, localized therapeutic delivery mechanism, SkinJect addresses significant patient pain points associated with traditional surgical excisions. This technology not only aims to improve patient compliance but also seeks to minimize the risk of recurrence, positioning the company as a disruptive force in dermatological oncology. As the prevalence of skin cancer continues to rise, SkinJect's focus on scalable, patient-centric solutions provides a distinct competitive advantage in a market historically reliant on invasive procedures.
How much funding has SkinJect raised?
SkinJect has raised a total of $1.5M across 1 funding round:
Unspecified
$1.5M
Unspecified (2021): $1.5M, investors not publicly disclosed
Key Investors in SkinJect
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for SkinJect?
Following this major enterprise-level funding, SkinJect is expected to prioritize the advancement of its clinical trials and the navigation of complex regulatory pathways required for commercialization. The strategic allocation of capital will likely support the scaling of manufacturing capabilities and the expansion of clinical data sets to validate the efficacy of the microneedle platform. As the company transitions from a development-focused entity to a commercial-ready organization, stakeholders will be monitoring the progress of regulatory filings and potential partnerships with established pharmaceutical distributors. The focus remains on achieving clinical milestones that demonstrate both safety and superior therapeutic outcomes, ultimately aiming to secure a dominant position in the treatment of basal cell carcinoma.
See full SkinJect company page
